Outcomes of CD19 CAR T cell therapy in patients with gastrointestinal tract involvement of large B cell lymphoma

Autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy has demonstrated the ability to produce durable remissions in patients with relapsed or refractory large B cell lymphoma (LBCL). There are currently three commercially available CAR T products for LBCL, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), with the third product, lisocabtagene maraleucel, recently approved.1-3 In the pivotal ZUMA-1 trial for axi-cel, 83% of patients had an objective response, with 39% of patients with ongoing response at a median follow up of 27.1 months.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research